Oncoinvent ASA and BerGenBio ASA Announce Strategic Merger and Rights Issue
In a significant development for the radiopharmaceutical sector, Oncoinvent ASA, a pioneering company specializing in radioactive micro particle suspensions for treating metastatic cancers in body cavities, has announced a strategic merger with BerGenBio ASA. This merger, set to be executed through a statutory process, positions BerGenBio as the acquiring entity. The announcement, made on June 30, 2025, marks a pivotal moment for both companies, promising to enhance their capabilities in the fight against cancer.
Merger Details and Strategic Implications
The merger agreement between BerGenBio ASA and Oncoinvent ASA is designed to consolidate their strengths in radiopharmaceutical cancer therapies. By combining resources, the newly formed entity aims to accelerate the development and commercialization of innovative cancer treatments. This strategic move is expected to leverage BerGenBio’s capital and listing on the Frankfurt Stock Exchange, thereby enhancing its market position and operational efficiency.
Rights Issue to Support Growth
Following the merger, the combined company plans to execute a fully underwritten rights issue. This financial maneuver is intended to raise approximately NOK 130 million, providing the necessary capital to support ongoing research and development initiatives. The rights issue will offer preferential subscription rights to existing shareholders, ensuring their continued investment in the company’s future growth.
Market Reaction and Future Outlook
Oncoinvent ASA, listed on the Frankfurt Stock Exchange, has seen its share price fluctuate over the past year, with a 52-week high of 0.278 EUR and a low of 0.0831 EUR. As of June 26, 2025, the close price stood at 0.148 EUR, with a market capitalization of approximately 11,983,333 EUR. The merger and subsequent rights issue are anticipated to stabilize and potentially enhance the company’s market valuation, reflecting investor confidence in the combined entity’s strategic direction.
Conclusion
The merger between BerGenBio ASA and Oncoinvent ASA represents a significant step forward in the radiopharmaceutical industry. By pooling their expertise and resources, the companies aim to drive innovation and improve treatment options for cancer patients. The fully underwritten rights issue will provide the financial foundation needed to support these ambitious goals, positioning the combined entity as a leader in the field. As the merger progresses, stakeholders will closely watch for developments that could further solidify the company’s market presence and impact on cancer therapy.